Therapeutic Cancer Vaccines Market Share to 2019 Available on Researchmoz.us

248 views

Published on

GBI Research, the leading business intelligence provider, has released its latest research “Therapeutic Cancer Vaccines Market to 2019 Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake”. There is currently only one marketed therapeutic cancer vaccine, Provenge, which is indicated for the treatment of castrate¬–resistant, asymptomatic metastatic prostate cancer which achieved global sales of approximately $215 million in 2011. Over the forecast period, numerous vaccines are anticipated to be approved over a range of indications including the commonly diagnosed lung and colorectal cancer types. All of these vaccines have been shown to improve patient survival, some by a few months, others by years. The high anticipated price tag of these vaccines will be a barrier of market growth. However, due to the fact that numerous vaccines are anticipated to be approved across a range of highly diagnosed indications, GBI Research believes the global market does have the potential to grow to a value of $7.8 billion by 2019

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
248
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
7
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Therapeutic Cancer Vaccines Market Share to 2019 Available on Researchmoz.us

  1. 1. Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended PatientSurvival, though High Prices May Limit UptakeTherapeutic Cancer Vaccines Market to 2019 Pipeline Indicates Safer Treatments and Extended PatientSurvival, though High Prices May Limit UptakeSummaryGBI Research, the leading business intelligence provider, has released its latest research “TherapeuticCancer Vaccines Market to 2019 Pipeline Indicates Safer Treatments and Extended Patient Survival, thoughHigh Prices May Limit Uptake”. There is currently only one marketed therapeutic cancer vaccine,Provenge, which is indicated for the treatment of castrate¬–resistant, asymptomatic metastatic prostatecancer which achieved global sales of approximately $215 million in 2011. Over the forecast period,numerous vaccines are anticipated to be approved over a range of indications including the commonlydiagnosed lung and colorectal cancer types. All of these vaccines have been shown to improve patientsurvival, some by a few months, others by years. The high anticipated price tag of these vaccines will be abarrier of market growth. However, due to the fact that numerous vaccines are anticipated to be approvedacross a range of highly diagnosed indications, GBI Research believes the global market does have thepotential to grow to a value of $7.8 billion by 2019.ScopeThe report analyzes treatment usage patterns, variation in vaccine type and pipeline and market forecastsacross indications for cancer vaccines. A brief introduction into cancer, its relation with the immune system,and a detailed outline of the 8 different types of cancer vaccines being developed, including their strengths andweaknesses. An analysis of Provenge, the only currently marketed therapeutic cancer vaccines, includingrecent sales figures and potential future competitors of Provenge. Comprehensive reviews of the pipeline fortherapeutic cancer vaccines with individual analyses on the most heavily researched and most commoncancers of melanoma, breast, prostate, colorectal, stomach and Non-small-cell lung cancer. The analysesinclude the phase distribution, the most common type of vaccine and most frequently observed moleculartarget for each indication. A statistical analysis of clinical trial duration and size by phase and by vaccine type.An in depth forecast model for each indication for which a vaccine is anticipated to be approved throughoutthe forecast period. Each model is based on the anticipated market performance of the vaccines to be approvedfor that indication. A detailed discussion of the drivers and barriers for this novel market.Reasons to buyThe report will assist business development and marketing executives to strategize their product launches,by allowing them to Understand the variation in the types of therapeutic cancer vaccines, and the strength andweaknesses of each form. Understand the vast scope of the pipeline, including which vaccine types andmolecular targets are generating the most interest. Observe the trends in clinical trial duration and sizeamongst Phases and vaccine types, and use the clinical trial failure rate analysis to assess the risk profiles ofcurrent and/or future developmental programs for therapeutic cancer vaccines. Observe the shift in clinicaltrial endpoints with Phase, and use this data to potentially influence any future developmental programs.Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the therapeuticcancer vaccines market.Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May L
  2. 2. table Of Contents1 Table Of Contents1 Table Of Contents 61.1 List Of Tables 91.2 List Of Figures 102 Introduction 112.1 Cancer Epidemiology 112.2 Disease Initiation And Propagation 112.3 Symptoms 122.3.1 Symptoms Of Lung Cancer 122.3.2 Symptoms Of Prostate Cancer 122.3.3 Symptoms Of Colorectal Cancer 122.3.4 Symptoms Of Breast Cancer 122.3.5 Symptoms Of Melanoma 122.3.6 Symptoms Of Stomach Cancer 122.4 Current Treatment And Management 132.4.1 Active Surveillance Or The ‘wait-and See’ Approach 132.4.2 Surgery 132.4.3 Radiation Therapy 132.4.4 Chemotherapy 132.4.5 Targeted Therapy 132.4.6 Hormone Therapy 142.4.7 Immunotherapy 142.5 Virally Induced Cancers And Prophylactic Vaccines 142.6 Cancer, The Immune System And Therapeutic Vaccines 152.6.1 Mechanisms Of Immune System Evasion 152.6.2 Mechanisms Of Immune System Disabling 152.7 Why Develop Therapeutic Cancer Vaccines? 162.8 Types Of Therapeutic Cancer Vaccine 162.8.1 Anti-idiotype Vaccines 162.8.2 Whole-cell-derived Vaccines 162.8.3 Cellular Immunotherapy 172.8.4 Antigen-based Vaccines 172.8.5 Dna-based Vaccines 172.8.6 Vector-based (microorganism-facilitated) Vaccines 172.8.7 Oncolytic Virus Vaccines 182.8.8 Adjuvants 18Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May L
  3. 3. 3 Marketed Products 193.1 Provenge – An Autologous Cellular Immunotherapy Vaccine For The Treatment OfHormone-refractory Prostate Cancer 193.1.1 Overview 193.1.2 Mechanism Of Action And Molecular Target 193.1.3 Formulation And Dosing 193.1.4 Provenge Within The Clinical Landscape For Prostate Cancer 193.1.5 Company Profile And Patent Expiry 203.2 Recent Sales And Commercialization Of Provenge 203.3 Current And Future Market Competitors For Provenge 224 Product Pipeline 244.1 Pipeline Overview 244.1.1 Developmental Pipeline Of All Major Indications 274.1.2 Clinical Trials 364.1.3 Clinical Trial Failure 414.1.4 Key Companies Developing Cancer Vaccines 444.1.5 Promising Drugs In The Developmental Pipeline 455 Forecasting 525.1 Therapeutic Cancer Vaccines Market To 2019 – Global 525.1.1 Treatment Usage Patterns 535.1.2 Annual Cost Of Treatment 535.2 Colorectal Cancer 535.2.1 Emerging Cancer Vaccines And Anticipated Treatment Usage Patterns 535.2.2 Annual Cost Of Therapy 545.2.3 Market Size 565.3 Glioblastoma Multiforme 585.3.1 Emerging Cancer Vaccines And Their Treatment Usage Patterns 585.3.2 Annual Cost Of Therapy 595.3.3 Market Size 605.4 Lymphoma 625.4.1 Emerging Cancer Vaccines For Lymphoma And Their Treatment Usage Patterns 625.4.2 Annual Cost Of Therapy 625.4.3 Market Revenues 645.5 Melanoma 665.5.1 Emerging Cancer Vaccines And Anticipated Treatment Usage Patterns 665.5.2 Annual Cost Of Therapy 675.5.3 Market Size 695.6 Non-small-cell Lung Cancer 715.6.1 Emerging Vaccines And Treatment Usage Patterns 71Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May L
  4. 4. 5.6.2 Annual Cost Of Therapy 715.6.3 Market Size 735.7 Pancreatic Cancer 745.7.1 Emerging Cancer Vaccines And Their Market Impact 745.7.2 Annual Cost Of Therapy 745.7.3 Market Revenues 765.8 Prostate Cancer 785.8.1 Treatment Usage Patterns And The Impact Of Emerging Vaccines 785.8.2 Annual Cost Of Treatment 785.8.3 Market Revenues 805.9 Drivers And Barriers For Therapeutic Cancer Vaccines Market 825.9.1 Drivers 825.9.2 Barriers 836 Appendix 856.1 Provenge Clinical Trial Titles (table 3) 856.2 Predicated Annual Cost Of Therapy 856.2.1 Colon Cancer 856.2.2 Glioblastoma Multiforme 856.2.3 Lymphoma 866.2.4 Melanoma 866.2.5 Non-small-cell Lung Cancer 876.2.6 Pancreatic Cancer 876.2.7 Prostate Cancer 886.3 Predicted Market Forecasts 886.3.1 Colon Cancer 886.3.2 Glioblastoma Multiforme 896.3.3 Lymphoma 896.3.4 Melanoma 906.3.5 Non-small-cell Lung Cancer 906.3.6 Pancreatic Cancer 916.3.7 Prostate 916.4 All Pipeline Drugs By Phase 926.4.1 Discovery 926.4.2 Preclinical 936.4.3 Ind-filed And Phase 0 956.4.4 Phase I 966.4.5 Phase Ii 1016.4.6 Phase Iii 1056.5 Market Definitions 1066.6 Abbreviations 1076.7 Sources 108Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May L
  5. 5. 6.8 Research Methodology 1116.8.1 Coverage 1116.8.2 Secondary Research 1116.8.3 Primary Research 1126.8.4 Therapeutic Landscape 1126.8.5 Epidemiology-based Forecasting 1126.8.6 Analogous Forecasting Methodology 1136.8.7 Diseased Population 1136.8.8 Prescription Population 1136.9 Market Size By Geography 1146.9.1 Forecasting Model For Therapeutic Areas 1146.10 Geographical Landscape 1156.11 Pipeline Analysis 1156.12 Expert Panel Validation 1156.13 Contact Us 1156.14 Disclaimer 115About Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMoz90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: http://researchmoz.blogspot.com/Website: http://www.researchmoz.us/Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May L

×